ATS 2019 Virtual Final Program

9:15 Insects on the Walls and Ceiling R. Abel, Nolensville, TN 9:30 Beyond Opioids: Multimodal Pain Management in the ICU J. Devlin, PharmD, Boston, MA 9:45 The Best Sedation is No Sedation and No Restraints S. Mehta, MD, Toronto, Canada 10:00 Delirium Treatment in 2019: Should We Just Say “No” to Drugs? T.D. Girard, MD, MSci, Pittsburgh, PA 10:15 Known Knowns and Known Unknowns in Early Mobility N.E. Brummel, MD, MSci, Nashville, TN 10:30 Supporting and Engaging Families: Strategies That Work D.B. White, MD, Pittsburgh, PA 10:45 Just Little Adults? H. Smith, MD, MSci, Nashville, TN 11:00 Bringing it All Together: Implementing the ABCDEF Bundle in the Real World M.A. Barnes-Daly, RN, BSN, CCRN, DC, Sacramento, CA BASIC • CLINICAL • TRANSLATIONAL BASIC SCIENCE CORE CME Credits Available: 2 B5 TILL DEATH DO US PART: CELL FATE AND OBSTRUCTIVE LUNG DISEASE Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Cell and Molecular Biology 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D Two (Level 3) Target Audience This session will benefit all providers of lung health including trainees. Individuals with a research focus on mechanisms of programmed cell death as it relates to obstructive lung disease should find the session of particular interest Objectives At the conclusion of this session, the participant will be able to: • learn new findings about programmed cell death and physiologic homeostasis in the lung; • apply knowledge about programmed cell death to understand the role it plays in obstructive lung disease; • learn new findings about how mechanisms of cell death may be novel targets for treatment of obstructive lung disease. The death and removal of inflammatory cells is a normal mechanism of maintaining homeostasis in the lung. The session will focus on the role of programmed cell death in obstructive lung diseases such as asthma and COPD. Common mechanisms of cell death including apoptosis, autophagy and regulation by cellular signaling will be discussed. The learner will understand that interruption of these normal processes can lead to enhanced inflammation. The session will also highlight how targeting the mechanisms of cell death may play a role in the treatment of obstructive lung diseases. Chairing: G.S. Skloot, MD, ATSF, New York, NY R.A. Panettieri, MD, New Brunswick, NJ I. Petrache, MD, ATSF, Denver, CO 9:15 A Time to Live and a Time to Die A.M.K. Choi, MD, New York, NY 9:45 Mechanisms of Cell Death in Asthma: Can Cells Live Too Long? C.A. Singer, PhD, Reno, NV 10:15 Programmed Cell Death in COPD: So Many Ways to Die I. Petrache, MD, ATSF, Denver, CO 10:45 Translating Death to Life: Opportunities for Precision Therapeutics in Airways Diseases R.A. Panettieri, MD, New Brunswick, NJ BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 B6 BORN TOO SOON: THE EFFECTS OF PREMATURITY ON THE NEONATAL/DEVELOPING LUNG Assemblies on Pediatrics; Respiratory Cell and Molecular Biology 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Dallas Ballroom A-C (Level 3) Target Audience Neonatologists, pediatric pulmonologists, basic researchers of lung development, pediatric pharmacists, neonatal and pediatric pulmonology fellows Objectives At the conclusion of this session, the participant will be able to: • understand the current thinking about the pathophysiology of bronchopulmonary dysplasia; • integrate the roles of the disciplines of neonatology and pulmonology in improving our understanding and care of babies with BPD; • identify future targets for additional research to increase our understanding of the developing lung. The Prematurity and Respiratory Outcomes Program (PROP) enrolled 835 preterm infants born less than 29 weeks gestation. Newborns were followed from birth until one year corrected gestational age. Scientific outcomes from these studies remains ongoing. This session will provide an update on current research findings and unpublished results. The studies focus on biomarkers for bronchopulmonary dysplasia (BPD) and later sequellae such as late onset pulmonary hypertension and pulmonary function abnormalities. Chairing: P.E. Moore, MD, ATSF, Nashville, TN A. Hamvas, MD, Chicago, IL 9:15 Introduction and the Effect of Race on BPD and Respiratory Outcomes R.M. Ryan, MD, ATSF, Charleston, SC ATS 2019 • Dallas, TX MONDAY • MAY 20 125 MONDAY MORNING